TY - JOUR
T1 - Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant Rejection
AU - Park, Jongmin
AU - Lin, Hsing-Ying
AU - Assaker, Jean Pierre
AU - Jeong, Sangmoo
AU - Huang, Chen-Han
AU - Kurdi, A
AU - Lee, Kyungheon
AU - Fraser, Kyle
AU - Min, Changwook
AU - Eskandari, Siawosh
AU - Routray, Sujit
AU - Tannous, Bakhos
AU - Abdi, Reza
AU - Riella, Leonardo
AU - Chandraker, Anil
AU - Castro, Cesar M
AU - Weissleder, Ralph
AU - Lee, Hakho
AU - Azzi, Jamil R
PY - 2017/11/28
Y1 - 2017/11/28
N2 - Kidney transplant patients require life-long surveillance to detect allograft rejection. Repeated biopsy, albeit the clinical gold standard, is an invasive procedure with the risk of complications and comparatively high cost. Conversely, serum creatinine or urinary proteins are noninvasive alternatives but are late markers with low specificity. We report a urine-based platform to detect kidney transplant rejection. Termed iKEA (integrated kidney exosome analysis), the approach detects extracellular vesicles (EVs) released by immune cells into urine; we reasoned that T cells, attacking kidney allografts, would shed EVs, which in turn can be used as a surrogate marker for inflammation. We optimized iKEA to detect T-cell-derived EVs and implemented a portable sensing system. When applied to clinical urine samples, iKEA revealed high level of CD3-positive EVs in kidney rejection patients and achieved high detection accuracy (91.1%). Fast, noninvasive, and cost-effective, iKEA could offer new opportunities in managing transplant recipients, perhaps even in a home setting.
AB - Kidney transplant patients require life-long surveillance to detect allograft rejection. Repeated biopsy, albeit the clinical gold standard, is an invasive procedure with the risk of complications and comparatively high cost. Conversely, serum creatinine or urinary proteins are noninvasive alternatives but are late markers with low specificity. We report a urine-based platform to detect kidney transplant rejection. Termed iKEA (integrated kidney exosome analysis), the approach detects extracellular vesicles (EVs) released by immune cells into urine; we reasoned that T cells, attacking kidney allografts, would shed EVs, which in turn can be used as a surrogate marker for inflammation. We optimized iKEA to detect T-cell-derived EVs and implemented a portable sensing system. When applied to clinical urine samples, iKEA revealed high level of CD3-positive EVs in kidney rejection patients and achieved high detection accuracy (91.1%). Fast, noninvasive, and cost-effective, iKEA could offer new opportunities in managing transplant recipients, perhaps even in a home setting.
KW - Biosensing Techniques/methods
KW - Exosomes/immunology
KW - Extracellular Vesicles/immunology
KW - Female
KW - Graft Rejection/immunology
KW - Humans
KW - Inflammation/immunology
KW - Kidney/immunology
KW - Kidney Transplantation/adverse effects
KW - Male
KW - Proteomics/methods
KW - T-Lymphocytes/immunology
U2 - 10.1021/acsnano.7b05083
DO - 10.1021/acsnano.7b05083
M3 - Article
C2 - 29053921
SN - 1936-0851
VL - 11
SP - 11041
EP - 11046
JO - Acs Nano
JF - Acs Nano
IS - 11
ER -